# Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus

> **NCT04069949** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sichuan University** · enrollment: 39 (estimated)

## Conditions studied

- Unresectable Hepatocellular Cancer
- Portal Vein Tumor Thrombus

## Interventions

- **DRUG:** sorafenib; toripalimab

## Key facts

- **NCT ID:** NCT04069949
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2020-10-01
- **Final completion:** 2021-10-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2019-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04069949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04069949, "Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04069949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*